QOPI® THE QUALITY ONCOLOGY PRACTICE INITIATIVE

Summary of Measures, Spring 2012

Module	#	Measure
Core	1	Pathology report confirming malignancy*
Core	2	Staging documented within one month of first office visit*
Core	3	Pain assessed by second office visit
Core	4a	Pain intensity quantified by second office visit (includes documentation of no pain)
Core	5	Plan of care for moderate/severe pain documented
Core	6	Pain addressed appropriately (defect-free measure, 3, 4a, and 5)*
Core	6a	Pain assessed on either of the two most recent office visits (**Test Measure**)
Core	6b	Pain intensity quantified on either of the two most recent office visits (**Test Measure**)
Core	6c	Plan of care for moderate/severe pain documented on either of the two most recent office visits (**Test Measure**)
Core	6d	Pain addressed appropriately on either of the two most recent office visits (defect-free measure, 6a, 6b, and 6c) (**Test Measure**)
Core	6e	Pain addressed appropriately by second office visit and during most recent office visits (defect-free measure, 6 and 6d) (**Test Measure**)
Core	7	Effectiveness of narcotic assessed on visit following prescription
Core	8	Constipation assessed at time of narcotic prescription or following visit
Core	9	Documented plan for chemotherapy, including doses, route, and time intervals*
Core	10	Chemotherapy intent (curative vs palliative) documented*
Core	11	Chemotherapy intent discussion with patient documented
Core	12	Number of chemotherapy cycles documented
Core	13	Chemotherapy planning completed appropriately (defect-free measure, 9, 10, and 12)
Core	13oral1	Documented plan for oral chemotherapy (defect-free measure, 13oral1a-13oral1e) (**Test Measure**)
Core	13oral1a	Documented plan for oral chemotherapy: dose (**Test Measure**)
Core	13oral1b	Documented plan for oral chemotherapy: administration schedule (days of treatment/rest and planned duration) (**Test Measure**)
Core	13oral1c	Documented plan for oral chemotherapy: lab and toxicity monitoring (**Test Measure**)
Core	13oral1d	Documented plan for oral chemotherapy: frequency of office visits/contacts (**Test Measure**)
Core	13oral1e	Documented plan for oral chemotherapy: provided to patient prior to start of therapy (**Test Measure**)
Core	13oral2	Oral chemotherapy education provided prior to the start of therapy (defect-free measure, 13oral2a-13oral2g) (**Test Measure**)
Core	13oral2a	Oral chemotherapy education provided prior to the start of therapy : safe handling (**Test Measure**)
Core	13oral2b	Oral chemotherapy education provided prior to the start of therapy : indications (**Test Measure**)
Core	13oral2c	Oral chemotherapy education provided prior to the start of therapy : schedule and start date (**Test Measure**)
Core	13oral2d	Oral chemotherapy education provided prior to the start of therapy : missed doses (**Test Measure**)

Last Updated: 2-1-2012

Module	#	Measure
Core	13oral2e	Oral chemotherapy education provided prior to the start of therapy : food and drug interactions (**Test Measure**)
Core	13oral2f	Oral chemotherapy education provided prior to the start of therapy : side effects and toxicities (**Test Measure**)
Core	13oral2g	Oral chemotherapy education provided prior to the start of therapy : clinic contact instructions (**Test Measure**)
Core	13oral3	Oral chemotherapy monitored on visit/contact following start of therapy (defect-free measure, 13oral3a-13oral3e) (**Test Measure**)
Core	13oral3a	Oral chemotherapy monitored on visit/contact following start of therapy: start date documented (**Test Measure**)
Core	13oral3b	Oral chemotherapy monitored on visit/contact following start of therapy: symptoms/toxicities assessed (**Test Measure**)
Core	13oral3c	Oral chemotherapy monitored on visit/contact following start of therapy: symptoms/toxicities addressed (**Test Measure**)
Core	13oral3d	Oral chemotherapy monitored on visit/contact following start of therapy: medication adherence assessed (**Test Measure**)
Core	13oral3e	Oral chemotherapy monitored on visit/contact following start of therapy: medication adherence addressed (**Test Measure**)
Core	14	Signed patient consent for chemotherapy
Core	15	Patient consent documented in practitioner note
Core	16	Patient consent for chemotherapy (combined measure, 14 or 15)
Core	17	Chemotherapy treatment summary completed within months of chemotherapy end
Core	18	Chemotherapy treatment summary provided to patient within months of chemotherapy end
Core	19	Chemotherapy treatment summary provided or communicated to practitioner(s) within months of chemotherapy end
Core	20	Chemotherapy treatment summary process completed within 3 months of chemotherapy end (defect-free measure, 17, 18, and 19)
Core	21a	Smoking status/tobacco use documented in past year*
Core	22a	Smoking/tobacco use cessation counseling recommended to smokers/tobacco users in past year
Core	23a	Smoking/tobacco use cessation administered appropriately in the past year(defect-free measure, 21a and 22a)
Core	24	Patient emotional well-being assessed by the second office visit*
Core	25	Action taken to address problems with emotional well-being by the second office visit
Core	25a	Documentation of patient's advance directives by the third office visit (**Test Measure**)
Symptom	26	Serotonin antagonist prescribed with moderate/high emetic risk chemotherapy
Symptom	27	Corticosteroids and serotonin antagonist prescribed with moderate/high emetic risk chemotherapy*
Symptom	28	Aprepitant prescribed with high emetic risk chemotherapy
Symptom	29	Anti-emetics prescribed appropriately with moderate/high emetic risk chemotherapy (defect-free measure, 27 and 28)
Symptom	30	Baseline iron stores documented within days prior to administration of ESAs

Module	#	Measure
Symptom	31	Hemoglobin < g/dL documented within weeks prior to administration of ESAs
Symptom	32	Appropriate documentation prior to administration of ESAs (defect-free measure, 30 and 31)
Symptom	33	Infertility risks discussed prior to chemotherapy with patients of reproductive age*
Symptom	34	Fertility preservation options discussed or referral to specialist
EOL	35	Pain assessed on either of the last two visits before death
EOL	36a	Pain intensity quantified on either of the last two visits before death (includes documentation of no pain)
EOL	37	Plan of care for moderate/severe pain documented on either of the last two visits before death
EOL	38	Pain assessed appropriately (defect-free measure, 35, 36a, and 37)*
EOL	39	Dyspnea assessed on either of the last two visits before death
EOL	40	Dyspnea addressed on either of the last two visits before death
EOL	41	Dyspnea addressed appropriately (defect-free measure, 39 and 40)
EOL	42	Hospice enrollment
EOL	43	Hospice enrollment or palliative care referral/services
EOL	44	Hospice enrollment within days of death (**Lower Score – Better**)
EOL	44a	Hospice enrollment and enrolled more than 3 days before death (defect-free measure, 42 and inverse 44)
EOL	45	Hospice enrollment within days of death (**Lower Score – Better**)
EOL	45a	Hospice enrollment and enrolled more than 7 days before death (defect-free measure, 42 and inverse 45)*
EOL	46	For patients not referred, hospice or palliative care discussed within the last months of life
EOL	47	Hospice enrollment, palliative care referral/services, or documented discussion (combined measure, 43 or 46)
EOL	48	Chemotherapy administered within the last weeks of life (**Lower Score – Better**)
Breast	49	Complete family history documented for patients with invasive breast cancer (defect-free measure, 49a-49c) (**Test Measure**)
Breast	49a	Presence or absence of cancer in first-degree blood relatives documented (**Test Measure**)
Breast	49b	Presence or absence of cancer in second-degree blood relatives documented (**Test Measure**)
Breast	49c	Age at diagnosis documented for each blood relative noted with cancer (**Test Measure**)
Breast	50	Percent of patients with invasive breast cancer with positive family history of breast cancer (**Test Measure**)
Breast	50a	Referral for or genetic testing for patients with invasive breast cancer (**Test Measure**)
Breast	51	Genetic testing addressed appropriately for patients with invasive breast cancer (defect-free measure, 51a-51c) (**Test Measure**)
Breast	51a	Genetic counseling, referral for counseling, or genetic testing for patients with invasive breast cancer with increased hereditary risk of breast cancer (**Test Measure**)
Breast	51b	Patient consent for genetic testing ordered by the practice for patients with invasive breast cancer (**Test Measure**)
Breast	51c	Patient with invasive breast cancer counseled, or referred for counseling, to discuss results following genetic testing (**Test Measure**)

Module	#	Measure
Breast	52	Chemotherapy recommended within months of diagnosis for women under with AJCC stage I (Tc) to III ER/PR negative breast cancer
Breast	53	Combination chemotherapy received within months of diagnosis by women under with AJCC stage I (Tc) to III ER/PR negative breast cancer**
Breast	54	Test for Her-2/neu overexpression or gene amplification*
Breast	55	Trastuzumab recommended for patients with AJCC stage I (Tc) to III Her-/neu positive breast cancer
Breast	56	Trastuzumab received when Her-/neu is negative or undocumented (**Lower Score – Better**)
Breast	56a	Trastuzumab not received when Her-/neu is negative or undocumented (inverse of 56)*
Breast	57	Trastuzumab received by patients with AJCC stage I (Tc) to III Her-/neu positive breast cancer**
Breast	58	Tamoxifen or AI recommended within year of diagnosis for patients with AJCC stage I (Tc) to III ER or PR positive breast cancer
Breast	59	Tamoxifen or AI received within year of diagnosis by patients with AJCC stage I (Tc) to III ER or PR positive breast cancer**
Breast	60	Tamoxifen or AI received when ER/PR status is negative or undocumented **(Lower Score – Better**)
Breast	61	IV bisphosphonates or denosumab administered for breast cancer bone metastases
Breast	62	Renal function assessed prior to the first administration of IV bisphosphonates or denosumab
Colorectal	62a	Presence or absence of cancer in first-degree blood relatives documented (**Test Measure**)
Colorectal	62b	Presence or absence of cancer in second-degree blood relatives documented (**Test Measure**)
Colorectal	62c	Age at diagnosis documented for each blood relative noted with cancer (**Test Measure**)
Colorectal	64	Referral for or genetic testing for patients with invasive colorectal cancer with positive family history of colorectal cancer (**Test Measure**)
Colorectal	64a	Percent of patients with invasive colorectal cancer tested or referred for genetic testing (**Test Measure**)
Colorectal	65	Genetic testing addressed appropriately for patients with invasive colorectal cancer (defect-free measure, 65a-65c) (**Test Measure**)
Colorectal	65a	Genetic counseling, referral for counseling, or genetic testing for patients with invasive colorectal cancer with increased hereditary risk of colorectal cancer (**Test Measure**)
Colorectal	65b	Patient consent for genetic testing ordered by the practice for patients with invasive colorectal cancer (**Test Measure**)
Colorectal	65c	Patient with invasive colorectal cancer counseled, or referred for counseling, to discuss results following genetic testing (**Test Measure**)
Colorectal	66	CEA within months of curative resection for colorectal cancer*
Colorectal	67	Adjuvant chemotherapy recommended within months of diagnosis for patients with AJCC stage III colon cancer
Colorectal	68	Adjuvant chemotherapy received within months of diagnosis by patients with AJCC stage III colon cancer**
Colorectal	69	Number of lymph nodes documented for resected colon cancer
Colorectal	70	12 or more lymph nodes examined for resected colon cancer

QOPI® Summary of Measures, Spring 2012

Module	#	Measure
Colorectal	71	Adjuvant chemotherapy recommended within months of diagnosis for patients with AJCC stage II or III rectal cancer
Colorectal	72	Adjuvant chemotherapy received within months of diagnosis by patients with AJCC stage II or III rectal cancer**
Colorectal	73	Colonoscopy before or within months of curative colorectal resection or completion of primary adjuvant chemotherapy*
Colorectal	74	KRAS testing for patients with metastatic colorectal cancer who received anti-EGFR MoAb therapy*
Colorectal	75	Anti-EGFR MoAb therapy received by patients with KRAS mutation (**Lower Score – Better**)
Colorectal	75a	Anti-EGFR MoAb therapy not received by patients with KRAS mutation (Inverse of)*
NHL	76	Granulocytic growth factor administered with CHOP to patients and older with NHL*
NHL	76a	Granulocytic growth factor administered on same day as CHOP to patients and older with NHL (**Lower Score – Better**)
NHL	77	Rituximab administered when CD- antigen expression is negative or undocumented (**Lower Score – Better**)
NHL	77a	Rituximab not administered when CD- antigen expression is negative or undocumented (Inverse of 77)*
NHL	78	Hepatitis B virus infection test including HBsAg documented prior to administration of rituximab for patients with NHL
NSCLC	79	Adjuvant chemotherapy recommended for patients with AJCC stage II or IIIA NSCLC
NSCLC	80	Adjuvant chemotherapy received by patients with AJCC stage II or IIIA NSCLC
NSCLC	81	Adjuvant cisplatin-based chemotherapy received within days after curative resection by patients with AJCC stage II or IIIA NSCLC
NSCLC	82	Adjuvant chemotherapy recommended for patients with AJCC stage IA NSCLC (**Lower Score - Better**)
NSCLC	83	Adjuvant radiation therapy recommended for patients with AJCC stage IB or II NSCLC (**Lower Score - Better**)
NSCLC	84	Performance status documented for patients with initial AJCC stage IV or distant metastatic NSCLC
NSCLC	85	Platinum doublet (or EGFR-TKI, with DNA mutation documented) first-line chemotherapy with or without targeted agent received by patients with initial AJCC stage IV or distant metastatic NSCLC with performance status of -without prior history of chemotherapy
NSCLC	86	Bevacizumab received by patients with initial AJCC stage IV or distant metastatic NSCLC with squamous histology (**Lower Score - Better**)
NSCLC	87	Disease status assessed by imaging documented prior to administration of the third cycle of first-line chemotherapy for patients with initial AJCC stage IV or distant metastatic NSCLC
NSCLC	88	Positive EGFR mutation for patients with stage IV NSCLC who received first-line EGFR tyrosine kinase inhibitor therapy
NSCLC	89	First-line EGFR tyrosine kinase inhibitor therapy received by patients with stage IV NSCLC in the absence of positive EGFR mutation (**Lower Score - Better**)

All measures are reported as percentages. *Included in QOPI Certification Program (**Adjuvant treatment measure)

Last Updated: 2-1-12